Current approach to hemochromatosis

Blood Reviews

Volumn 22, Issue 4, 2008, Pages 195-210

  Brissot, Pierre ^a   Troadec, Marie Bérengère ^a   Bardou Jacquet, Edouard ^a   Lan, Caroline Le ^a   Jouanolle, Anne Marie ^a,b   Deugnier, Yves ^a   Loréal, Olivier ^a  

^a INSERM   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Ferroportin; Hemochromatosis; Hemojuvelin; Hepcidin; HFE; Iron overload; Saturation ferritin; Transferrin; Transferrin receptor 2; Venesection

Indexed keywords

CERULOPLASMIN; DEFERASIROX; DEFERIPRONE; FERROPORTIN; HEPCIDIN; IRON; IRON CHELATING AGENT;

ARTICLE; DISEASE CLASSIFICATION; GENETIC ANALYSIS; HEMOCHROMATOSIS; HUMAN; IRON OVERLOAD; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PHLEBOTOMY; PRIORITY JOURNAL;

ANTIMICROBIAL CATIONIC PEPTIDES; BENZOIC ACIDS; CATION TRANSPORT PROTEINS; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MEMBRANE PROTEINS; PHLEBOTOMY; TRIAZOLES;

EID: 43949090838     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2008.03.001     Document Type: Article

References (123)

1. Feder J.N., Gnirke A., Thomas W., et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13 (1996) 399-408
2. Brissot P., Troadec M.B., and Loreal O. The clinical relevance of new insights in iron transport and metabolism. Curr Hematol Rep 3 (2004) 107-115
3. Loreal O., Haziza-Pigeon C., Troadec M.B., et al. Hepcidin in iron metabolism. Curr Protein Pept Sci 6 (2005) 279-291
4. Camaschella C. Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood 106 (2005) 3710-3717
5. Deugnier Y, Brissot P, Loréal O. Iron and the Liver: Update 2008. J Hepatol 2008:in press.
6. OMIM. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=omim.
7. Brissot P, Le Lan C, Troadec MB, et al.: Diagnosis and Treatment of HFE-haemochromatosis. In: Handbook ESoH, ed. Disorders of Iron homeostasis, Erythrocytes, Erythropoiesis, 2006.
8. Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology 46 (2007) 1291-1301
9. Merryweather-Clarke A.T., Pointon J.J., Shearman J.D., and Robson K.J. Global prevalence of putative haemochromatosis mutations. J Med Genet 34 (1997) 275-278
10. Poddar S. Hereditary hemochromatosis-Special reference to Indian scenario. Int J Human Genet 6 (2006) 73-79
11. Dhillon B.K., Das R., Garewal G., et al. Frequency of primary iron overload and HFE gene mutations (C282Y, H63D and S65C) in chronic liver disease patients in north India. World J Gastroenterol 13 (2007) 2956-2959
12. Waalen J., Nordestgaard B.G., and Beutler E. The penetrance of hereditary hemochromatosis. Best Pract Res Clin Haematol 18 (2005) 203-220
13. Beutler E., Felitti V.J., Koziol J.A., Ho N.J., and Gelbart T. Penetrance of 845G-> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 359 (2002) 211-218
14. Adams P.C., Reboussin D.M., Barton J.C., et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 352 (2005) 1769-1778
15. Powell L.W., Dixon J.L., Ramm G.A., et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 166 (2006) 294-301
16. Asberg A., Hveem K., Halvorsen T.B., and Smethurst H.B. Prevalence of liver fibrosis and cirrhosis in screening-detected C282Y homozygous subjects. Scand J Gastroenterol 42 (2007) 782-783
17. van der A.D., Peeters P.H., Grobbee D.E., Roest M., Voorbij H.A., and van der Schouw Y.T. HFE genotypes and dietary heme iron: no evidence of strong gene-nutrient interaction on serum ferritin concentrations in middle-aged women. Nutr Metab Cardiovasc Dis 16 (2006) 60-68
18. Cade J.E., Moreton J.A., O'Hara B., et al. Diet and genetic factors associated with iron status in middle-aged women. Am J Clin Nutr 82 (2005) 813-820
19. Kaltwasser J.P., Werner E., Schalk K., Hansen C., Gottschalk R., and Seidl C. Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis. Gut 43 (1998) 699-704
20. Barton J.C., Preston B.L., McDonnell S.M., and Rothenberg B.E. Severity of iron overload in hemochromatosis: effect of volunteer blood donation before diagnosis. Transfusion 41 (2001) 123-129
21. Distante S., Berg J.P., Lande K., Haug E., and Bell H. HFE gene mutation (C282Y) and phenotypic expression among a hospitalised population in a high prevalence area of haemochromatosis. Gut 47 (2000) 575-579
22. Beutler E., Waalen J., and Gelbart T. Chronic inflammation does not appear to modify the homozygous hereditary hemochromatosis phenotype. Blood Cells Mol Dis 35 (2005) 326-327
23. Beutler E., and Gelbart T. Helicobacter pylori infection and HFE hemochromatosis. Blood Cells Mol Dis 37 (2006) 188-191
24. Detivaud L., Nemeth E., Boudjema K., et al. Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood 106 (2005) 746-748
25. Bridle K., Cheung T.K., Murphy T., et al. Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease. Alcohol Clin Exp Res 30 (2006) 106-112
26. Harrison-Findik D.D., Schafer D., Klein E., et al. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J Biol Chem 281 (2006) 22974-22982
27. Laine F., Jouannolle A.M., Morcet J., et al. Phenotypic expression in detected C282Y homozygous women depends on body mass index. J Hepatol 43 (2005) 1055-1059
28. Bekri S., Gual P., Anty R., et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 131 (2006) 788-796
29. Hutchinson C., Geissler C.A., Powell J.J., and Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 56 (2007) 1291-1295
30. Moirand R., Adams P.C., Bicheler V., Brissot P., and Deugnier Y. Clinical features of genetic hemochromatosis in women compared with men. Ann Intern Med 127 (1997) 105-110
31. Deugnier Y., Jouanolle A.M., Chaperon J., et al. Gender-specific phenotypic expression and screening strategies in C282Y-linked haemochromatosis: a study of 9396 french people. Br J Haematol 118 (2002) 1170-1178
32. Olynyk J.K., Cullen D.J., Aquilia S., Rossi E., Summerville L., and Powell L.W. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 341 (1999) 718-724
33. Asberg A., Hveem K., Thorstensen K., et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 36 (2001) 1108-1115
34. Levy J.E., Montross L.K., and Andrews N.C. Genes that modify the hemochromatosis phenotype in mice. J Clin Invest 105 (2000) 1209-1216
35. Bensaid M., Fruchon S., Mazeres C., Bahram S., Roth M.P., and Coppin H. Multigenic control of hepatic iron loading in a murine model of hemochromatosis. Gastroenterology 126 (2004) 1400-1408
36. Tolosano E., Fagoonee S., Garuti C., et al. Haptoglobin modifies the hemochromatosis phenotype in mice. Blood 105 (2005) 3353-3355
37. Jacolot S., Le Gac G., Scotet V., Quere L., Muraz C., and Ferec C. HAMP as a modifier gene that increase the phenotypic expression of the HFE C282Y homozygous genotype. Blood 103 (2004) 2340-2385
38. Merryweather-Clarke A.T., Cadet E., Bomford A., et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet 12 (2003) 2241-2247
39. Le Gac G., Scotet V., Ka C., et al. The recently identifiedtype 2A juvenile haemochromatosis gene (HJV), a seconf candidate modifier of the C282Y homozygous phenotype. Hum Mol Genet 13 (2004) 1913-1918
40. Millet J., Dehais V., Bourgain C., et al. Common variants in the BMP2, BMP4, and HJV genes of the hepcidin regulation pathway module HFE hemochromatosis penetrance. Am J Human Genet 81 (2007) 799-807
41. Lee P., Gelbart T., West C., Halloran C., and Beutler E. Seeking candidate mutations that affect iron homeostasis. Blood Cells Mol Dis 29 (2002) 471-487
42. Carter K., Bowen D.J., McCune C.A., and Worwood M. Haptoglobin type neither influences iron accumulation in normal subjects nor predicts clinical presentation in HFE C282Y haemochromatosis: phenotype and genotype analysis. Br J Haematol 122 (2003) 326-332
43. Kelleher T., Ryan E., Barrett S., O'Keane C., and Crowe J. DMT1 genetic variability is not responsible for phenotype variability in hereditary hemochromatosis. Blood Cells Mol Dis 33 (2004) 35-39
44. Gochee P.A., Powell L.W., Cullen D.J., Du Sart D., Rossi E., and Olynyk J.K. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology 122 (2002) 646-651
45. Walsh A., Dixon J.L., Ramm G.A., et al. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clin Gastroenterol Hepatol 4 (2006) 1403-1410
46. Papanikolaou G., Samuels M.E., Ludwig E.H., et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 36 (2004) 77-82
47. Roetto A., Papanikolaou G., Politou M., et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 33 (2003) 21-22
48. Roetto A., Totaro A., Piperno A., et al. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood 97 (2001) 2555-2560
49. Girelli D., Bozzini C., Roetto A., et al. Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene. Gastroenterology 122 (2002) 1295-1302
50. Majore S., Milano F., Binni F., et al. Homozygous p.M172K mutation of the TFR2 gene in an Italian family with type 3 hereditary hemochromatosis and early onset iron overload. Haematologica 91 (2006) ECR33
51. Pietrangelo A. The ferroportin disease. Blood Cells Mol Dis 32 (2004) 131-138
52. Wallace D.F., and Subramaniam V.N. Non-HFE haemochromatosis. World J Gastroenterol 13 (2007) 4690-4698
53. Montosi G., Donovan A., Totaro A., et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 108 (2001) 619-623
54. Njajou O.T., Vaessen N., Joosse M., et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 28 (2001) 213-214
55. Barton J.C., Acton R.T., Lee P.L., and West C. SLC40A1 Q248H allele frequencies and Q248H-associated risk of non-HFE iron overload in persons of sub-Saharan African descent. Blood Cells Mol Dis 39 (2007) 206-211
56. Beutler E., Barton J.C., Felitti V.J., et al. Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans. Blood Cells Mol Dis 31 (2003) 305-309
57. Rivers C.A., Barton J.C., Gordeuk V.R., et al. Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin in African Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Blood Cells Mol Dis 38 (2007) 247-252
58. Subramaniam V.N., Wallace D.F., Dixon J.L., Fletcher L.M., and Crawford D.H. Ferroportin disease due to the A77D mutation in Australia. Gut 54 (2005) 1048-1049
59. Koyama C., Wakusawa S., Hayashi H., et al. A Japanese family with ferroportin disease caused by a novel mutation of SLC40A1 gene: hyperferritinemia associated with a relatively low transferrin saturation of iron. Intern Med 44 (2005) 990-993
60. Hsiao P.J., Tsai K.B., Shin S.J., et al. A novel mutation of transferrin receptor 2 in a Taiwanese woman with type 3 hemochromatosis. J Hepatol 47 (2007) 303-306
61. Agarwal S., Sankar V.H., Tewari D., and Pradhan M. Ferroportin (SLC40A1) gene in thalassemic patients of Indian descent. Clin Genet 70 (2006) 86-87
62. Wallace D.F., Clark R.M., Harley H.A., and Subramaniam V.N. Autosomal dominant iron overload due to a novel mutation of ferroportin1 associated with parenchymal iron loading and cirrhosis. J Hepatol 40 (2004) 710-713
63. Sham R.L., Phatak P.D., West C., Lee P., Andrews C., and Beutler E. Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. Blood Cells Mol Dis 34 (2005) 157-161
64. Miyajima H., Takahashi Y., and Kono S. Aceruloplasminemia, an inherited disorder of iron metabolism. Biometals 16 (2003) 205-213
65. Yoshida K., Furihata K., Takeda S., et al. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat Genet 9 (1995) 267-272
66. Kono S., Suzuki H., Takahashi K., et al. Hepatic iron overload associated with a decreased serum ceruloplasmin level in a novel clinical type of aceruloplasminemia. Gastroenterology 131 (2006) 240-245
67. Knisely A.S., Gelbart T., and Beutler E. Molecular characterization of a third case of human atransferrinemia. Blood 104 (2004) 2607
68. Mims M.P., Guan Y., Pospisilova D., et al. Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood 105 (2005) 1337-1342
69. Beaumont C., Delaunay J., Hetet G., Grandchamp B., de Montalembert M., and Tchernia G. Two new human DMT1 gene mutations in a patient with microcytic anemia, low ferritinemia, and liver iron overload. Blood 107 (2006) 4168-4170
70. Iolascon A., d'Apolito M., Servedio V., Cimmino F., Piga A., and Camaschella C. Microcytic anemia and hepatic iron overload in a child with compound heterozygous mutations in DMT1 (SCL11A2). Blood 107 (2006) 349-354
71. Camaschella C., Campanella A., De Falco L., et al. The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload. Blood 110 (2007) 1353-1358
72. Krause A., Neitz S., Magert H.J., et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 480 (2000) 147-150
73. Park C.H., Valore E.V., Waring A.J., and Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276 (2001) 7806-7810
74. Pigeon C., Ilyin G., Courselaud B., et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 276 (2001) 7811-7819
75. Peyssonnaux C., Zinkernagel A.S., Datta V., Lauth X., Johnson R.S., and Nizet V. TLR4-dependent hepcidin expression by myeloid cells in response to bacterial pathogens. Blood 107 (2006) 3727-3732
76. Nemeth E., Valore E.V., Territo M., Schiller G., Lichtenstein A., and Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101 (2003) 2461-2463
77. Nicolas G., Viatte L., Bennoun M., Beaumont C., Kahn A., and Vaulont S. Hepcidin, A New Iron Regulatory Peptide. Blood Cells Mol Dis 29 (2002) 327-335
78. Ganz T. Molecular control of iron transport. J Am Soc Nephrol 18 (2007) 394-400
79. Andrews N.C., and Schmidt P.J. Iron homeostasis. Annu. Rev. Physiol. 69 (2006) 16.11-16.17
80. Nemeth E., Tuttle M.S., Powelson J., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306 (2004) 2090-2093
81. Rivera S., Nemeth E., Gabayan V., Lopez M.A., Farshidi D., and Ganz T. Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood (2005) 2196-2199
82. Courselaud B., Pigeon C., Inoue Y., et al. C/EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism. J Biol Chem 277 (2002) 41163-41170
83. Babitt J.L., Huang F.W., DM W., et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 38 (2006) 531-539
84. Wang R., Li C., Xu X., et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab 2 (2005) 399-409
85. Truksa J, Peng H, Lee P, Beutler E. Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin1 expression independently of Hfe, transferrin receptor 2. Proc Natl Acad Sci U S A 2006:10289-10293.
86. Goswami T., and Andrews N.C. Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J Biol Chem 281 (2006) 28494-28498
87. Calzolari A., Raggi C., Deaglio S., et al. TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway. J Cell Sci 119 (2006) 4486-4498
88. Silvestri L., Pagani A., and Camaschella C. Furin mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood (2007)
89. Valore E.V., and Ganz T. Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin. Blood Cells Mol Dis 40 (2008) 132-138
90. Nicolas G., Bennoun M., Devaux I., et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 98 (2001) 8780-8785
91. Papanikolaou G., Tzilianos M., Christakis J.I., et al. Hepcidin in iron overload disorders. Blood 105 (2005) 4103-4105
92. Hershko C., Graham G., Bates G.W., and Rachmilewitz E.A. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 40 (1978) 255-263
93. Hider R.C. Nature of nontransferrin-bound iron. Eur J Clin Invest 32 Suppl 1 (2002) 50-54
94. Brissot P., Wright T.L., Ma W.L., and Weisiger R.A. Efficient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states. J Clin Invest 76 (1985) 1463-1470
95. Esposito B.P., Breuer W., Sirankapracha P., Pootrakul P., Hershko C., and Cabantchik Z.I. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 102 (2003) 2670-2677
96. Le Lan C., Loreal O., Cohen T., et al. Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood 105 (2005) 4527-4531
97. Drakesmith H., Schimanski L.M., Ormerod E., et al. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood 106 (2005) 1092-1097
98. De Domenico I., Ward D.M., Musci G., and Kaplan J. Iron overload due to mutations in ferroportin. Haematologica 91 (2006) 92-95
99. De Domenico I., Ward D.M., di Patti M.C., et al. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. Embo J 26 (2007) 2823-2831
100. Moirand R., Kerdavid F., Loreal O., et al. Regulation of ferritin expression by alcohol in a human hepatoblastoma cell line and in rat hepatocyte cultures. J Hepatol 23 (1995) 431-439
101. Mendler M.H., Turlin B., Moirand R., et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 117 (1999) 1155-1163
102. Loreal O, Nemeth E, Le Lan C, et al. Abnormal expression of hepcidin during genetic hemochromatosis, alcoholic cirrhosis,and dysmetabolic hepatosiderosis-Abstract. International Bio-Iron Society.Kyoto.April, 1-6,2007. Am J Hematol 2008;in press.
103. Ferrante M., Geubel A., Fevery J., Marogy G., Horsmans Y., and Nevens F. Hereditary hyperferritinaemia-cataract syndrome: a challenging diagnosis for the hepatogastroenterologist. Eur J Gastroenterol Hepatol 17 (2005) 1247-1253
104. Pinto L., Kagalwala F., Singh S., Balakrishnan C., Prabhu S.V., and Khodaiji S. Macrophage activation syndrome: experience from a tertiary referral centre. J Assoc Physicians India 55 (2007) 185-187
105. Gandon Y., Olivié D., Guyader D., et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 33 (2004) 338-343
106. St Pierre T.G., Clark P.R., Chua-anusorn W., et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105 (2005) 855-861
107. Pietrangelo A., Corradini E., Ferrara F., et al. Magnetic resonance imaging to identify classic and nonclassic forms of ferroportin disease. Blood Cells Mol Dis 37 (2004) 192-196
108. Deugnier Y., and Turlin B. Pathology of hepatic iron overload. World J Gastroenterol 13 (2007) 4755-4760
109. Sebastiani G., and Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 12 (2006) 3682-3694
110. Stauber R.E., and Lackner C. Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C. World J Gastroenterol 13 (2007) 4287-4294
111. Deugnier Y., Loreal O., Carre F., et al. Increased body iron stores in elite road cyclists. Med Sci Sports Exerc 34 (2002) 876-880
112. Tanno T., Bhanu N.V., Oneal P.A., et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 13 (2007) 1096-1101
113. Piperno A., Girelli D., Nemeth E., et al. Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. Blood 110 (2007) 4096-4100
114. Piperno A., Roetto A., Mariani R., et al. Homozygosity for transferrin receptor-2 Y250X mutation induces early iron overload. Haematologica 89 (2004) 359-360
115. Le Gac G., Mons F., Jacolot S., Scotet V., Ferec C., and Frebourg T. Early onset hereditary hemochromatosis resulting from a novel TFR2 gene nonsense mutation (R105X) in two siblings of north French descent. Br J Haematol 125 (2004) 674-678
116. HAS. French recommendations for management of HFE hemochromatosis. Haute Autorité de Santé 2005; www.has-sante.fr.
117. Brissot P., and de Bels F. Current approaches to the management of hemochromatosis. Hematology Am Soc Hematol Educ Program (2006) 36-41
118. Loreal O., Turlin B., Pigeon C., et al. Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. J Hepatol 36 (2002) 851-856
119. Roberts DJ, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev 2007:CD004839.
120. Henter J.I., and Karlen J. Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood 109 (2007) 5157-5159
121. Cappellini M.D., Cohen A., Piga A., et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 107 (2006) 3455-3462
122. Adams P.C., Reboussin D.M., Press R.D., et al. Biological variability of transferrin saturation and unsaturated iron-binding capacity. Am J Med 120 (2007) 999 e991-999 e997
123. Waalen J., Felitti V.J., Gelbart T., and Beutler E. Screening for hemochromatosis by measuring ferritin levels: a more effective approach. Blood (2007)